Explore

Trendline Trendline
Eli Lilly Acquires Ajax Therapeutics for $2.3 Billion to Expand Blood Cancer Treatment Pipeline

Eli Lilly Acquires Ajax Therapeutics for $2.3 Billion to Expand Blood Cancer Treatment Pipeline

Eli Lilly Acquires Ajax Therapeutics for $2.3 Billion to Expand Blood Cancer Treatment Pipeline
Reuters Reuters
Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion in blood cancer bet

Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion in blood cancer bet

By Christy Santhosh April 27 (Reuters) - Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up to $2.3 billion in cash, as the U.S. drugmaker looks to expand its oncology pipeline.
Trendline Trendline
Sun Pharma Acquires U.S. Firm Organon in $11.75 Billion Deal

Sun Pharma Acquires U.S. Firm Organon in $11.75 Billion Deal

Sun Pharma Acquires U.S. Firm Organon in $11.75 Billion Deal
Rapid Read Rapid Read
Chronic Myelomonocytic Leukemia: Understanding Extramedullary Disease

Chronic Myelomonocytic Leukemia: Understanding Extramedullary Disease

Chronic myelomonocytic leukemia (CMML) is a complex blood cancer characterized by monocytosis and marrow dysplasia. A significant aspect of CMML is the occurrence of extramedullary disease (EMD), where cancerous cells infiltrate areas outside the bone marrow. This condition is often underrecognized but can significantly impact patient outcomes, leading to increased morbidity and a higher risk of acute myeloid leukemia transformation. EMD is associated with specific genetic mutations and inflammatory processes, necessitating a comprehensive diagnostic approach that includes imaging and biopsy.
Trendline Trendline
Verastem Oncology to Announce Q1 2026 Financial Results Amid Cancer Drug Development

Verastem Oncology to Announce Q1 2026 Financial Results Amid Cancer Drug Development

Verastem Oncology to Announce Q1 2026 Financial Results Amid Cancer Drug Development
Trendline Trendline
Vir Biotechnology Announces Upcoming Conference Call for Q1 2026 Financial Results

Vir Biotechnology Announces Upcoming Conference Call for Q1 2026 Financial Results

Vir Biotechnology Announces Upcoming Conference Call for Q1 2026 Financial Results
Trendline Trendline
CatalYm Initiates Phase 2/3 Trial for Visugromab in Cancer Cachexia Treatment

CatalYm Initiates Phase 2/3 Trial for Visugromab in Cancer Cachexia Treatment

CatalYm Initiates Phase 2/3 Trial for Visugromab in Cancer Cachexia Treatment
Rapid Read Rapid Read
CatalYm Initiates Phase 2/3 Trial for Visugromab in Cancer Cachexia Treatment

CatalYm Initiates Phase 2/3 Trial for Visugromab in Cancer Cachexia Treatment

CatalYm has commenced a Phase 2/3 trial for its anti-GDF-15 antibody, visugromab, targeting cancer-associated cachexia. The VINCIT trial aims to enroll 518 patients with cachexia linked to advanced cancers such as non-small cell lung cancer and colorectal cancer. Cachexia, characterized by severe weight loss and muscle wasting, affects up to 70% of cancer patients and contributes to 20-40% of cancer-related deaths. Visugromab works by neutralizing GDF-15, a cytokine involved in immune suppression and cachexia. The trial will assess the efficacy of visugromab in reversing cachexia, with primary endpoints including changes in body weight and appetite.
Rapid Read Rapid Read
Former Senator Ben Sasse Attributes Extended Life to Experimental Cancer Treatment

Former Senator Ben Sasse Attributes Extended Life to Experimental Cancer Treatment

Former U.S. Senator Ben Sasse, diagnosed with stage 4 metastatic pancreatic cancer, credits an experimental drug for extending his life beyond initial expectations. Diagnosed in December and given a prognosis of three to four months, Sasse has seen a 76% reduction in tumor size due to a clinical trial involving the drug daraxonrasib. This treatment, developed by Revolution Medicines, has extended the life expectancy of patients from six to approximately thirteen months. Sasse discussed his journey and the impact of this treatment in an interview with Scott Pelley on '60 Minutes,' highlighting the role of faith and medical innovation in his ongoing battle with cancer.
Rapid Read Rapid Read
Study Reveals Heart's Beating Motion Inhibits Cancer Growth in Mice

Study Reveals Heart's Beating Motion Inhibits Cancer Growth in Mice

A recent study published in Science has found that the mechanical action of the heart's beating may prevent cancer growth in this organ, explaining the rarity of heart tumors in mammals, including humans. Researchers transplanted hearts onto the necks of genetically modified mice, where they did not beat but still received blood supply. Cancer cells injected into these transplanted hearts proliferated significantly, unlike in the native beating hearts. This suggests that the mechanical strain of the heart's beating could inhibit tumor growth. The study provides a compelling explanation for the low incidence of cardiac tumors, which are found in less than 1% of human autopsies.
Rapid Read Rapid Read
Heart's Mechanical Forces Found to Suppress Tumor Growth, Offering New Cancer Therapy Insights

Heart's Mechanical Forces Found to Suppress Tumor Growth, Offering New Cancer Therapy Insights

Researchers at the International Centre for Genetic Engineering and Biotechnology have discovered that the heart's constant beating may suppress tumor growth in cardiac tissues. The study highlights the role of mechanical forces in altering gene regulation in cancer cells, preventing their proliferation. Central to this process is the protein Nesprin-2, which transmits mechanical signals that reduce cancer cell activity. The findings suggest potential new cancer therapies based on mechanical stimulation.
Rapid Read Rapid Read
DPP4 Deficiency in AML Mice Alters Leukemic Stem Cell Behavior and Distribution

DPP4 Deficiency in AML Mice Alters Leukemic Stem Cell Behavior and Distribution

Recent research has identified DPP4 as a significant factor in the behavior and distribution of leukemic stem cells (LSCs) in acute myeloid leukemia (AML) models. The study found that DPP4 deficiency in AML mice leads to a redistribution of leukemic cells within the bone marrow, moving them from the metaphysis to the central marrow. This redistribution is associated with increased cell-cycle activity and a loss of LSC quiescence, resulting in higher rates of apoptosis. The findings suggest that DPP4 plays a crucial role in maintaining LSCs by supporting their survival and self-renewal capabilities. The study highlights the potential of targeting DPP4 as a therapeutic strategy in AML treatment.